The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 17, 2024
Filed:
Jul. 23, 2019
Applicant:
Novartis Ag, Basel, CH;
Inventors:
Christopher Farady, Basel, CH;
Nina Gommermann, Lörrach, DE;
Philipp Janser, Basel, CH;
Angela MacKay, Basel, CH;
Henri Mattes, Michelbach le Bas, FR;
Nikolaus Johannes Stiefl, Lörrach, DE;
Juraj Velcicky, Basel, CH;
Assignee:
Novartis AG, Basel, CH;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/53 (2006.01); A61K 31/616 (2006.01); A61K 45/06 (2006.01); C07D 495/14 (2006.01); C07D 513/14 (2006.01); C07D 515/14 (2006.01);
U.S. Cl.
CPC ...
A61K 31/53 (2013.01); A61K 31/616 (2013.01); A61K 45/06 (2013.01); C07D 495/14 (2013.01); C07D 513/14 (2013.01); C07D 515/14 (2013.01);
Abstract
The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R, Rand Rare defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.